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ABSTRACT 
 
Purpose: To analyze the patterns offailure and the toxicity profile of intraoperative 
electron beam radiotherapy (IOERT) after resection of soft tissue sarcomas of the 
extremities (STS). 
Patients and methods: Forty-five patients with extremity STS were treated with 
IOERT and moderate-dose postoperative radiotherapy (45–50 Gy). Twenty-six patients 
were treated for primary disease (PD) and 19 patients for an isolated recurrence (ILR). 
Tumor size was > 5 cm (maximum diameter) in 36 patients (80%), and high-grade 
histology in PD patients was present in 14 patients (54%). In nine patients, IOERT was 
used alone, due to previous irradiation or patient refusal. Chemotherapy (neoadjuvant 
and/or adjuvant) was mainly given to high-grade tumors. 
Results: Nine patients relapsed in the extremity (20%), and 12 patients in distant sites 
(28%). Actuarial local control at 5 years was 88% for patients with negative/close 
margins and 57% for patients presenting positive margins (P = 0.04). Five patients 
(11%) developed neuropathy associated with the treatment. Extremity preservation was 
achieved in 40 patients (88%). With a median follow-up of 93 months (range: 27–143 
months) for the patients at risk, 25 patients remain alive (a 7-year actuarial survival rate 
of 75% for PD and 47% for ILR; P = 0.01). 
Conclusions: IOERT combined with moderate doses of external beam irradiation yields 
high local control and extremity preservation rates in resected extremity STS. Peripheral 
nerves in the IOERT field are dose-limiting structures requiring a dose compromise in 
the IOERT component to avoid severe neurological damage. 
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1. INTRODUCTION 
 
Intraoperative electron beam radiation therapy (IOERT) is an innovative boosting 
technique used to deliver single high-doses of irradiation (range of 10–20 Gy) in 
selected anatomic areas identified during the surgical procedure as high risk and/or 
residual disease sites, while avoiding surrounding dose-limiting structures. Studies of 
IOERT in multiple anatomical sites have produced valuable and reproducible results in 
terms of locoregional control and toxicity [6]. The potential advantage of using IOERT 
in retroperitoneal sarcomas has been explored and reported by institutions experienced 
in its use [19,22]. The NCI trial on retroperitoneal sarcomas reported improved local 
control rates and decreased incidence of enteritis, understood to be related to a lower 
external beam radiotherapy (EBRT) dose in the IOERT arm (35–40 Gy compared with 
50–55 Gy in the EBRT-only arm) [19]. One of the advantages of IOERT was that the 
intra-abdominal organs could be protected from receiving full doses of irradiation, with 
a subsequent decrease in the incidence of severe enteritis and an increase in the local 
control rates [22]. 
  
The of use of a radiation boost in the extremities has been explored with the use of low-
dose rate brachytherapy [8], but published results using electrons are limited. IOERT as 
part of a multidisciplinary approach to treating soft tissue sarcomas (STS) of the 
extremities has several theoretical advantages: 
1. The delivery of the boost dose to the tumor bed after resection shortens the 
overall radiation treatment time. 
2. The external beam irradiation (EBRT) dose component delivered to normal 
tissues can be decreased. 
3. The IOERT dose component is selectively and exclusively given to a highly 
controlled thickness of tissue in the tumor bed area. 
 
The present analysis describes a study with long-term follow-up in an institution with 
prospective treatment policy of IOERT boost plus modest EBRT doses postoperatively. 
 
 
2. PATIENTS AND METHODS  
 
2.1. Inclusion criteria 
 
Between December 1986 and September 1994, 45 patients with extremity STS were 
treated with IOERT as a component of their radiation treatment. Only patients with 
resected extremity STS were included (patients with tumors arising in the gluteal or 
shoulder regions were excluded). All patients gave informed consent before study entry. 
The endpoint of the study was to evaluate patterns of failure, long-term side effects and 
secondarily the survival of a group of patients treated with IOERT as a boost in STS of 
the extremities. 
 
Twenty-six patients had primary soft tissue sarcoma (PD) without distant metastasis at 
IORT, and 19 patients had an isolated local recurrence (ILR) after surgery. Patients with 
prior postoperative adjuvant treatments such as radiotherapy and/or chemotherapy were 
allowed to enter the study. Work-up to rule out metastatic disease included complete 
blood count, biochemical profile, chest X-ray, and/or thoracic and abdominal computed 
tomography. 
Patient characteristics are shown in Table 1. The anatomical treatment sites included the 
upper extremity in eight patients and the lower extremity in 37 patients. Tumor 
characteristics are described in Tables 2 and 3. Malignant fibrous histiocytoma was the 
predominant histologic type in 13 patients; liposarcoma was found in 12 patients. Three 
patients had recurrent aggressive fibromatosis. The predominant tumor stage was IIIb 
(29%). Eighty percent of the lesions were larger than 5 cm in maximum dimension. 
Fourteen patients with PD (54%) had grade III tumors. 
 
Thirteen patients underwent re-resection after presumed initial incomplete surgery. In 
nine of these, residual tumor was found. The other 32 patients underwent de novo 
surgery for primary or recurrent disease. The final surgical procedure at the time of 
IORT was considered as wide removal in 28 cases, marginal resection in 13 cases and 
compartmental resection in three cases. In one patient, radical surgery was not feasible. 
Close resection margins (< 5 mm) were found in eight patients and involved margins in 
seven patients (Table 4). 
 
 
2.2. IOERT characteristics 
 
The IOERT methodology has been described in detail elsewhere [3]. Applicator size 
was selected to encompass the entire surgical bed. If the surgical bed was extremely 
large, i.e. exceeding the available applicator size, either abutting fields were used or 
only the high-risk areas (the surgical tumor bed closer to the resection margin) defined 
by the surgeon were boosted. Electron beam energies were selected depending upon the 
amount of residual tumor. Usually, 6–9 MeV beams were used for high-risk areas or 
microscopic residual disease and 12–15 MeV for suspected macroscopic residue. The 
dose depended upon the amount of residual disease present; an IOERT boost dose of 
10–15 Gy was delivered in areas with negative or close margins, and greater than 15 Gy 
was given in areas of macroscopic residual disease. 
  
Since 1992, our treatment regimen has included displacing the peripheral nerves, i.e. 
moving them out of the IOERT field. If the nerves could not be physically displaced or 
if there was a risk of devitalizing the structure, then the IOERT nerve dose was limited 
to 10 Gy, and the nerves were protected with pliable lead sheets for the remaining 
component of the IOERT dose. 
 
Fifty-six IOERT fields were treated in 45 patients. Ten patients were treated with 
multiple abutting fields, taking special care to avoid overlap (median number of fields 
was 2, range: 2–4). The main objective when using multiple IOERT fields was to avoid 
overlapping. The percentage of tissue overlapped never was over a few millimeters. The 
median applicator diameter, energy, and dose used were 9 cm, 9 MeV, and 15 Gy, 
respectively (Table 5). In 16 patients, the main neurovascular bundle was irradiated with 
IOERT. In all these 16 patients, nerve displacement and/or direct tumor contact was 
documented in the preoperative staging imaging studies, indicating the need for 
supplemental radiation due to the absence of wide tumor-free surgical margins. 
 
 
 
 
 
2.3. External beam irradiation 
 
Patients were scheduled for external irradiation 3–5 weeks after surgery. Field 
arrangement was designed to encompass the entire surgical scar and the surgical tumor 
bed. Standard fractionation of 1.8–2 Gy, 5 days per week to a total EBRT dose of 40–60 
Gy was used. Mixed photons and electron beams were occasionally used to optimize 
dosimetry within the target volume. In patients with prior irradiation, IOERT was used 
as the only radiation treatment component. Preoperative irradiation was used in one 
patient with a multicentric recurrent liposarcoma of the lower limb. In nine patients, the 
EBRT treatment was not administered, due to prior full-dose adjuvant EBRT (Table 5). 
 
 
2.4. Chemotherapy 
 
Patients with high-grade tumors or recurrent histologies were given adjuvant 
chemotherapy either preoperatively (10 patients) and/or postoperatively (23 patients). 
Sixteen patients with PD and seven patients with ILR received adjuvant chemotherapy. 
Neoadjuvant chemotherapy consisted of three courses of intra-arterial cisplatinum 50 
mg/m
2
 and Doxorubicin 40 mg/m
2
 i.v. every 28 days. Adjuvant chemotherapy consisted 
of 6–12 monthly cycles of Ifosfamide (1.5 g/m2 days 1–3), Doxorubicin (50 mg/m2 day 
1), and Dacarbazine (400 mg/m
2
 i.v. days 1–3). 
 
 
2.5. Toxicity 
 
The toxicities noted include only those potentially related to local effects from local 
treatments. Toxicity related to chemotherapy is not included. Patients with suspected 
neuropathy underwent close follow-up with periodic neurological evaluation. Toxicity 
was recorded following the Common Toxicity Criteria, version 2.0. 
 
  
2.6. Statistical analysis 
 
Survival analysis was performed using the Kaplan–Meier method [10]. Differences in 
survival and local control rates were assessed by the log-rank test in univariate analysis 
[13]. 
 
 
 
3. RESULTS 
 
3.1. Patterns of failure 
 
For the entire group, Isolated local recurrence was detected in six patients (13%), 
combined local failure and distant metastasis in three patients (7%), and distant 
metastasis alone in 11 patients (24%). Three local failures (12%) were observed in the 
PD group, compared to six (31%) in the ILR group (P = not significant (n.s.)). The rates 
of distant metastasis were similar among groups (23% in PD and 37% in ILR, P = n.s.). 
Two of the nine local failures were found in the subcutaneous tissue (outside the IOERT 
boost). Five of nine local failures were observed in recurrent tumors, and seven of nine 
occurred in tumors initially larger than 5 cm. Of the nine local failures diagnosed, four 
had a successful local salvage treatment: in two patients, the limb was amputated; one 
patient received chemotherapy and local re-irradiation; and one received surgery and re-
irradiation. Most patients presenting distant failure had lung metastases (11 patients). 
Other metastatic sites were the liver, bone, and kidney. One patient developed a second 
primary, a pancreatic tumor. The median time interval to local recurrence after IOERT 
was 20 months (range: 3–125 months); for distant metastasis, this was 18 months 
(range: 4–138 months). 
 
Five-year actuarial local control was strongly related to the status of the surgical 
margins. Eighty-eight percent of the patients with negative/close margins and 57% with 
positive margins were controlled (P = 0.04) (Fig. 1). The initial disease status showed a 
trend for improved local control. Patients with PD had an 88% 5-year actuarial local 
control, compared to 60% for the ILR group (P = 0.05) (Fig. 2). Furthermore, patients 
receiving adjuvant EBRT had a slightly superior local control rate (85%) than those 
patients in whom EBRT was omitted (74%) (P = 0.09). 
 
Patients with high-grade primary tumors showed a trend for improved control rate 
(93%) than patients with low-grade primaries (83%) or recurrent tumors (75%), (P = 
0.1). 
 
The initial size of the tumor, histological grade, location (upper vs. lower extremity), 
and sex were not associated with significant differences in local failure. 
 
 
3.2. Survival analysis 
 
At the time of this analysis, 29 patients remain alive. With a median follow-up of 93 
months for the surviving patients (limits: 27–143 months), 7-year actuarial survival for 
PD is 75% and 47% for the ILR subset (P = 0.01). (Fig. 3). In univariate analysis, only 
histological grade and disease status showed a trend as a prognostic factor for long-term 
survival. Patients with low grade tumors had a 92% 7 year survival compared to 70% 7-
year survival for patients with high grade tumors, and 47% 7-year survival for ILR 
patients (P = 0.05). Tumor size was not a predictor of long-term survival, probably 
because of the small sample size. Patients with T1 tumors had an 85% 5-year survival, 
compared to 63% for patients with T2 tumors (P = 0.2). Surgical margins did not 
significantly affect survival. The 5 year survival was 65% in those patients with 
negative or close margins and 71% in those patients with positive margins. 
 
 
3.3. Toxicity and functional status of the extremity 
 
EBRT-induced radiation dermatitis (grade II–III) occurred in nine patients. Four 
patients developed soft tissue necrosis requiring skin-graft for repair. Delayed wound 
healing occurred in four patients. EBRT was not delayed by postoperative 
complications. One patient with a seroma developed swelling of the irradiated area, 
fever, and impairment of the function in the extremity 40 months after surgery. No local 
recurrence was demonstrated and symptoms disappeared with antibiotics. 
 
Late toxicity was evaluated in those patients at risk who survived more than one year 
after IOERT (31 patients evaluable). The two major complications observed were 
amputation and neuropathy. In three patients, severe toxicity required amputation. Two 
patients developed ischemia and symptomatic fibrosis, which was associated with 
neuropathy in one. Both patients presented with a large tumor mass at diagnosis (8 and 
10 cm maximum diameter, respectively) and amputation of the extremity would 
otherwise have been the first treatment option using standard criteria. The third amputee 
developed an isolated local recurrence that was managed with reirradiation, which 
induced severe normal tissue toxicity that required amputation for symptomatic control 
(Table 6). 
 
Five patients developed neurotoxicity. The median time to the onset of neurotoxicity 
was 13 months (range: 8 – 21 months). It was grade 1 (paresthesia not interfering with 
daily life) in one patient and grade 3–4 (objective weakness and/or sensory loss or 
paresthesia interfering with daily life) in the remaining four. No patient had paralysis 
(sensory grade 4). In three cases, the nerve had been included in the IOERT field. The 
chance of developing neuropathy was present in three out of 12 patients (25%) if the 
peripheral nerve had been included in the IOERT field and in two out of 18 patients 
(11%) if the nerve had not been irradiated. In four of five patients with nerve damage, 
the tumor size and the IOERT dose selected were greater than 12 cm and > 15 Gy, 
respectively. Three of the five patients showed symptomatic recovery 12 months after 
the onset of neuropathy (two partial, one total) (Table 7). 
 
Of the 31 evaluable patients, 24 (77%) have a functional extremity without limitations 
for daily activities. Four patients walk with crutches, and five have a functionally 
impaired extremity due to toxicity after treatment: three amputations and two non-
reversible neuropathies. Two patients with initial severe neuropathy have improved over 
time and lead a normal daily life. The final extremity preservation rate was 88% (40 out 
of 45 patients) (Table 8). 
 
 
 
4. DISCUSSION 
 
Initial positive experiences with both the feasibility of and tolerance to IOERT in the 
treatment of tumors arising in several anatomical sites prompted the investigation of 
IOERT in extremity STS [2,3]. Technical considerations, such as the optimal access of 
the IOERT applicators into the surgical bed and the highly controllable dosimetry of 
electrons in flat surfaces, led to inclusion of this modality as an intraoperative radiation 
component. Another possible advantage of IOERT is that it can be administered as an 
up-front radiation boost, simultaneously with surgical resection, which might allow total 
EBRT dose to be decreased without jeopardizing local control or survival. 
 
IOERT clinical trials have been mainly conducted on patients with locally advanced 
malignancies in the abdomen and pelvis [6,14]. IOERT improves the therapeutic ratio 
by decreasing the toxicity in dose-limiting normal tissues that can be displaced or 
protected during IOERT. IOERT might indirectly improve the quality of therapy, as a 
secondary endpoint, by decreasing the overall treatment time [19]. This increase in the 
therapeutic ratio may also translate into survival benefit, especially in cancer sites with 
high risk of isolated loco-regional relapse [1]. The contribution of local control to 
survival in patients with extremity STS is controversial [17,20]. However, quality of life 
is an important endpoint in these patients and is particularly dependent on strategies 
providing high local control rates, which translates into extremity preservation. 
 
Scarce data exist regarding local control, tissue tolerance, effectiveness, feasibility, and 
functional status after treatment with IOERT in extremity STS [21]. The present report 
describes long-term follow-up results obtained in a cohort of patients treated with 
IOERT. The 20% local failure rate obtained is similar to the 15–20% reported in 
contemporary reports of EBRT-only series [7]. Furthermore, the observed 12% rate in 
primary tumors is among the best results described in published series using 
conventional multimodal treatment. The experience with IOERT in soft tissue sarcomas 
of the extremities is limited. In a recent update of the Mayo Clinic experience, Petersen 
et al. reported a 4% local failure rate for primary tumors and 17% for recurrent tumors 
using a comparable methodological approach [15]. Eble et al. reported an 8% local 
failure for stage IIB–IIIB tumors [15] and Dubois et al. reported no local recurrences in 
a smaller series of 18 STS patients treated with an IOERT component [4]. 
 
The present data are derived from a low number of patients in each disease category, 
which does make difficult the assessment of real prognostic information. In this 
particular group of patients, surgical margins have been closely related to local failure, a 
factor that has been previously reported [9,16]. However, the optimal radiation dose 
required to control macroscopic residual disease is still unknown. IOERT trials have not 
yet been able to determine whether a dose-control relationship in resected STS is related 
to the amount of residual disease. This uncertainty applies to both to the IOERT and 
EBRT radiation components. 
 
The addition of chemotherapy in the treatment of highgrade sarcomas may have 
contributed to improved local control rates. Combined treatment modalities increase the 
effect of radiation significantly, achieving significant improvement in local control and 
survival in other human tumors [11]. In the present study, 55% of the patients received 
concurrent chemotherapy and irradiation. A recent published meta-analysis suggested 
that adjuvant chemotherapy significantly reduced the metastasis rate and contributed to 
decrease the incidence of local failure [18]. This metaanalysis estimation showed a 27% 
reduction in the risk of local recurrence, which corresponded to an estimated absolute 
survival benefit of 6% at 10 years. 
 
Acute toxicity was minor in the present study, and postoperative complications caused 
no delays in the initiation of the EBRT. Late effects described in this series may be 
difficult to analyzed as severe normal tissue complications are understood as 
multifactorial in origin and cannot be attributed to a single treatment modality. Severe 
late effects led to amputation in three patients. It can be speculated that an amputation 
would have been the best treatment option due to the initial tumor extent, which made 
them poor candidates for extremity preservation. One patient presented with a second 
recurrence of a desmoid tumor in which free surgical margins were not obtained. 
Furthermore, four IOERT fields were used, and vascular damage with immediate repair 
was reported during surgery. Amputation was done below the zone treated with external 
irradiation. In a second case, amputation was performed after obtaining a poor 
functional outcome. This patient, who had positive resection margins, presented 
recurrent disease after one previous course of irradiation. Therefore, other causes 
besides IOERT may also have contributed to the toxicity that led to amputation in these 
cases. 
 
Neuropathy is a dose-limiting toxicity in IOERT for extremity STS and other anatomic 
sites treated with this modality. Animal studies have shown that the tolerance of nerve 
structures to IOERT may be lower than 15 Gy [12]. In these studies, 30% of the animals 
developed neuropathy with IOERT doses of 15 Gy. In the present series, doses of 
IOERT greater than 10 Gy combined with external irradiation of 40–50 Gy were 
considered to be potentially harmful to nerve tissues. Sixteen percent of the patients 
developed symptoms associated with peripheral neuropathy. In three of these patients, 
substantial improvement was observed over time, with successful recovery after 
prolonged follow-up. Our current policy mandates, as the first technical option, 
displacing any nerve included in the target. If this cannot be done or if the nerve 
structure might be damaged by traction or perineural dissection, then a 5 Gy dose is 
delivered without shielding, followed by 10 Gy with shielding (individualized lead 
layers). Conversely, if the nerve is considered to be in a low risk area, it is shielded for 
the entire procedure. The data reported in this study are previous to the activation of the 
nerve protection policies. 
 
A possible advantage of using IOERT as a boosting technique is the reduction in the 
overall treatment time. Only two patients in the entire series received an EBRT 
component total dose higher than 50 Gy, which is an EBRT value lower than 
recommended in the radical management of STS [5]. IOERT boost does shorten the 
overall treatment time, with the additional potential advantage of facilitating the 
integration of chemo-radiation segments in the initial part of the multidisciplinary 
treatment. 
 
In conclusion, the present data demonstrate that IOERT as a boosting technique in the 
radical management of extremity STS is feasible and showing local control rates 
comparable to those reported in the treatment of other tumor sites approached with 
IOERT. The toxicity described in the present series is acceptable; however, careful 
attention should be paid to peripheral nerves as specific IOERT doselimiting structures. 
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 Table 1. Patient characteristics and site of the 
intraoperative electron beam radiotherapy 
(IOERT) boost 
 n % 
Number 45  
Age (years)   
Median 42  
Range 11–78  
Sex   
Male 26 58 
Female 19 42 
KPS > 70% 45 100 
Location   
Upper limb 8 18 
Lower limb 37 82 
KPS, Karnofsky performance status. 
 
 
 
 
Table 2. Histology in primary sarcoma and isolated local 
recurrences treated with IOERT 
Histology Primary ILR Total 
Liposarcoma 6 6 12 
MFH 7 6 13 
Synovial sarcoma 3 1 4 
Rhabdomyosarcoma 3 - 3 
Fibrosarcoma 3 1 4 
Hemangiopericytoma 3 - 3 
Alveolar sarcoma 1 - 1 
Leiomyosarcoma - 2 2 
Aggressive fibromatosis - 3 3 
MFH, malignant fibrous histiocytoma 
ILR, isolated local recurrence 
 
 
 
 
 
 
 
 Table 3. Tumor characteristics 
Tumor type n % 
Primary 26 58 
AJCC stage   
IA 2 4 
IB 8 18 
IIB 2 4 
IIIA 1 2 
IIIB 13 29 
ILR 19 22 
Size   
T1 8 18 
T2 36 80 
N/A 1 2 
Grade (primary tumors)   
I–II 12 46 
III 14 54 
 
 
 
 
Table 4. Type of surgery during the                    
IOERT procedure 
 n % 
Type of surgery   
Wide 28 62 
Marginal 13 28 
Compartmental 3 6 
Not specified 1 2 
Surgical margins   
Negative 30 67 
Close (<5 mm) 8 20 
Positive 7 13 
 
 
 
 
 
 
 
 Table 5. IOERT and external beam radiotherapy                  
(EBRT) characteristics 
IOERT n % 
No. of IOERT fields 56  
Single 35 78 
Multiple 10 22 
Applicator diameter (cm)   
5–7 14 25 
8–9 4 7 
10–15 38 68 
Energy (MeV)   
6–9 40 71 
10–15 14 25 
20 2 4 
Dose (Gy)   
10–12 24 43 
15 24 43 
20 8 14 
External beam radiotherapy (Gy)   
30 1 2 
40–45 8 18 
46–50 25 56 
> 50 2 4 
No EBRT 9 20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 6. Toxicity related to local treatment 
 n (%) 
Acute   
Infection 4 9 
Dermatitis 2 4 
Soft tissue necrosis 4 9 
Delayed wound healing 4 9 
Late   
Neuropathy 5 11 
Symptomatic fibrosis 2 4 
Amputation 3 7 
Bone fracture 2 4 
Edema 2 4 
Toxicity related to chemotherapy is not shown. 
 
 
 
 
 
Table 7. Treatment parameters involved in neuropathy                  
development in evaluable patients followed more than                                            
12 months with extremity preserved 
Parameter Total Neuropathy % 
IOERT field 31 5 16 
Nerve included 12 3 25 
Nerve excluded 18 2 11 
Unknown 1 – – 
IOERT applicator size (cm)    
6–10  1  
12  3  
12  1  
Dose (Gy)    
10  1  
15  3  
20  1  
 
 
 
 
 
  
Table 8. Extremity outcome data: functionality and amputation evaluation 
Functional outcome 
Primary ILR 
Total % 
n % n % 
Impairment       
None 13 29 7 16 20 45 
Minor 4 9 - - 4 9 
Major 4 9 3 7 7 16 
Not evaluable 5 11 9 20 14 31 
 
 n Total % Comments 
Limb preservation 40 45 88  
Amputation due to toxicity 3 45 7 Four IOERT fields, one reirradiation 
Amputation due local failure 2 45 4  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Actuarial local control according to surgical margins. 
 
 
 
 
 
Figure 2. Actuarial local control according to sarcoma status (primary vs. isolated local 
recurrence (ILR)). 
 
 
 
Figure 3. Actuarial survival in patients with primary soft tissue sarcoma and ILR,         
P = 0.01 
 
 
 
 
 
